Emerging immunologic approaches as cancer anti-angiogenic therapies

• Published in: Clinical & translational oncology
• Main Authors: Azimi, Mohammadreza, Manavi, Mahdokht Sadat, Afshinpour, Maral, Khorram, Roya, Vafadar, Reza, Rezaei-Tazangi, Fatemeh, Arabzadeh, Danyal, Arabzadeh, Sattar, Ebrahimi, Nasim, Aref, Amir Reza
• Format: Journal Article
• Language: English
• Published: Italy 18-09-2024
• Subjects: Nanoparticles; Chimeric antigen receptor T cells (CART); Antiangiogenic vaccines; Immune checkpoint inhibitors; Immunotherapy
• ISSN: 1699-3055; 1699-3055
• DOI: 10.1007/s12094-024-03667-2

Targeting tumor angiogenesis, the formation of new blood vessels supporting cancer growth and spread, has been an intense focus for therapy development. However, benefits from anti-angiogenic drugs like bevacizumab have been limited by resistance stemming from activation of compensatory pathways. Recent immunotherapy advances have sparked interest in novel immunologic approaches that can induce more durable vascular pruning and overcome limitations of existing angiogenesis inhibitors. This review comprehensively examines these emerging strategies, including modulating tumor-associated macrophages, therapeutic cancer vaccines, engineered nanobodies and T cells, anti-angiogenic cytokines/chemokines, and immunomodulatory drugs like thalidomide analogs. For each approach, the molecular mechanisms, preclinical/clinical data, and potential advantages over conventional drugs are discussed. Innovative therapeutic platforms like nanoparticle delivery systems are explored. Moreover, the importance of combining agents with distinct mechanisms to prevent resistance is evaluated. As tumors hijack angiogenesis for growth, harnessing the immune system's specificity to disrupt this process represents a promising anti-cancer strategy covered by this review.